MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension.

ABSTRACT: PURPOSE   : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda^®) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort^®) ophthalmic solution in the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT).

Methods

MERCURY-3 was a 6-month prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (≥ 18 years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP ≥ 17 mmHg in ≥ 1 eye and < 28 mmHg in both eyes) were included. Following washout, patients were randomized to once-daily NET/LAT or BIM/TIM for up to 6 months; efficacy was

SUBMITTER: Stalmans I 

PROVIDER: S-EPMC10806046 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature